|Spark Therapeutics Inc -- USA Stock|| |
USD 67.51 5.10 8.17%
Co-Founder and CTO
Dr. J. Fraser Wright Ph.D. is CoFounder and Chief Technology Officer of Spark Therapeutics Inc. From July 2013 until he joined Spark Dr. Wright served as our Chief Technology Advisor. Dr. Wright established and had been the director of the Clinical Vector Core Laboratory at CHOP from 2004 to January 2015. Dr. Wright also was a Professor at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wright previously served as Director of Development and Clinical Manufacturing at Avigen Inc. from 1999 to 2004 and as scientist with Sanofi Pasteur and as scholar investigator with the Canadian blood services
Age: 56 Founder Since 2015 Ph.D
Wright received his B.S. and Ph.D. in biochemistry from the University of Toronto.
The company has return on total asset (ROA)
of (29.55) %
which means that it has lost $29.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (60.07) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 36.22 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics Inc has Current Ratio of 9.73 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 315 people.Spark Therapeutics Inc (ONCE) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 315 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.